Tirzepatide Dosing Guide: 2026 Mounjaro & Zepbound

If you have just been prescribed tirzepatide , or you are researching it before your next appointment, this is the dosing guide we wish every patient had on day one. Tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, sleep apnea, and (Phase 3 clinical investigation for) heart failure with preserved ejection fraction, is the most prescribed GLP-1 medication in the United States in 2026. It is also the most misunderstood, because the same molecule shows up under two brand names, in pens and vials, at six different dose strengths, and increasingly in compounded formulations from telehealth pharmacies. In this guide we walk through the official FDA titration schedule, how to do the reconstitution math without getting it wrong, what the side effects actually look like at each dose, and how the legal landscape for compounded tirzepatide shifted after the October 2024 shortage resolution. Use it as a reference, then talk to your prescriber.
Table of Contents
- What is tirzepatide?
- How tirzepatide works
- Dosing protocol (Mounjaro and Zepbound titration schedule)
- Reconstitution math for compounded vials
- Side effects and management
- Drug interactions
- Cycle Lengths
- Lab Monitoring
- Storage & Travel
- Common stacks and combinations
- 2026 regulatory status
- Cost considerations
- Frequently asked questions
What is tirzepatide?
Tirzepatide is a once-weekly injectable peptide developed by Eli Lilly. It is a dual agonist , meaning a single molecule that activates two gut-hormone receptors, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). It comes in two FDA-approved brands, both containing the identical active ingredient at identical strengths:
- Mounjaro , approved for type 2 diabetes mellitus.
- Zepbound , approved for chronic weight management, obstructive sleep apnea in adults with obesity (added December 2024), and heart failure with preserved ejection fraction in adults with obesity is being investigated in the Phase 3 SUMMIT trial (Packer et al., NEJM 2025; 393:427-437). Lilly withdrew the HFpEF supplemental application to FDA in May 2025; HFpEF is not currently an FDA-approved indication.
If your insurance covers Mounjaro for diabetes but not Zepbound for weight loss, that is a coverage decision, not a clinical one. The drug in the syringe is the same.
How tirzepatide works
GLP-1 and GIP are hormones your gut releases after you eat. They tell your pancreas to release insulin, signal your brain that you are full, and slow how quickly food leaves your stomach. By activating both receptors at once, tirzepatide produces stronger appetite suppression and better glucose control than activating GLP-1 alone, which is why head-to-head data from the SURPASS-2 trial (Frías et al., NEJM 2021; 385:503–515) showed tirzepatide outperforming semaglutide on both A1c reduction and weight loss.
The plasma half-life is approximately 117 hours (about 5 days), per Urva et al., Clin Pharmacokinet 2022; 61:1057–1067. Steady-state blood levels are reached at roughly 4 weeks of weekly dosing, which is why every step in the titration schedule is held for a minimum of 4 weeks before moving up.
Dosing protocol
Both Mounjaro and Zepbound use the identical FDA titration schedule, sourced from the Mounjaro USPI (Eli Lilly, revised November 2024) and the Zepbound USPI (revised December 2025).
| Phase | Weeks | Weekly Dose | Purpose |
|---|---|---|---|
| Initiation | 1–4 | 2.5 mg | Tolerability only, not a therapeutic dose |
| Step 1 | 5–8 | 5 mg | First maintenance option |
| Step 2 (optional) | 9–12 | 7.5 mg | Bridge dose |
| Step 3 (optional) | 13–16 | 10 mg | Second maintenance option |
| Step 4 (optional) | 17–20 | 12.5 mg | Bridge dose |
| Maintenance (max) | 21+ | 15 mg | Maximum studied dose |
A few important nuances:
- The 2.5 mg starting dose is not therapeutic. It exists to let your gut adapt to GIP/GLP-1 activation before any meaningful appetite suppression kicks in.
- The label lists 5, 10, and 15 mg as the “core” maintenance doses. The 7.5 mg and 12.5 mg “bridge” doses are intended as tolerability rest stops, but real-world data, including the SURMOUNT-4 maintenance trial (Aronne et al., JAMA 2024; 331:38-48) , shows many patients maintain effective weight control at 7.5 or 10 mg without ever needing 15 mg.
- Each step requires at least 4 weeks before moving up. Going faster does not get you to steady state any faster, it just front-loads side effects.
- If you miss a dose: take it within 4 days of the missed day; if more than 4 days have passed, skip it and resume on your regular day. Never double up. (Mounjaro USPI §2.4, Zepbound USPI §2.4.)
Mounjaro and Zepbound pens vs. Zepbound vials
Branded Mounjaro and Zepbound KwikPens are pre-filled, single-use auto-injectors at all six dose strengths (2.5, 5, 7.5, 10, 12.5, 15 mg). You do not reconstitute anything. You uncap, click, and inject.
In 2024, Lilly launched Zepbound single-dose vials at 2.5 mg and 5 mg through LillyDirect at a lower price point. These vials ship pre-mixed as liquid (not lyophilized powder), so there is no reconstitution, you simply draw the labeled volume into an insulin syringe. As of February 2026, Lilly expanded vial availability to include 2.5, 5, 7.5, and 10 mg strengths; 12.5 mg and 15 mg remain pen-only.
Reconstitution math for compounded vials
This section only applies if you are using compounded tirzepatide from a 503A or 503B pharmacy, typically dispensed through a telehealth platform. Brand pens require no math at all.
Compounded tirzepatide ships as a lyophilized (freeze-dried) powder in a sealed glass vial. You add bacteriostatic water (BAC water, sterile water with 0.9% benzyl alcohol as a preservative) to dissolve the powder, then draw your dose into a U-100 insulin syringe.
The two formulas you need
Concentration: total mg in vial ÷ mL of BAC water added = mg per mL.
Units on a U-100 syringe: (dose in mg ÷ concentration in mg/mL) × 100. The result is the number of insulin-syringe units you draw.
Common compounded tirzepatide configurations
| Vial total | BAC water added | Resulting concentration | 5 mg dose volume | Units (U-100) |
|---|---|---|---|---|
| 10 mg | 1 mL | 10 mg/mL | 0.50 mL | 50 units |
| 20 mg | 2 mL | 10 mg/mL (Henry Meds default) | 0.50 mL | 50 units |
| 30 mg | 1.5 mL | 20 mg/mL | 0.25 mL | 25 units |
| 40 mg | 2 mL | 20 mg/mL | 0.25 mL | 25 units |
| 60 mg | 3 mL | 20 mg/mL (Mochi default) | 0.25 mL | 25 units |
A worked example
You have a 20 mg vial. Your prescriber instructs you to add 2 mL of BAC water. Concentration is 20 ÷ 2 = 10 mg/mL. Your prescribed dose is 7.5 mg weekly. Volume = 7.5 ÷ 10 = 0.75 mL. On a U-100 insulin syringe, that is 75 units.
Want to skip the arithmetic? Our peptide reconstitution calculator (live now at calculator.thepeptidetoolkit.com) does this in two clicks and flags common error conditions, like volumes that exceed a single insulin syringe or doses below the limit of accurate measurement. The calculator cannot, however, tell you what dose is right for your body. That is your prescriber’s job.
Reconstitution mistakes to avoid
- Confusing mg with units. A U-100 syringe is marked in insulin units, not milligrams. 100 units equals 1 mL. Patients who try to “draw 5 mg” by reading the syringe markings as milligrams can inject 10× their intended dose.
- Adding the wrong volume of BAC water. If your prescriber said 2 mL and you add 1 mL, every dose is now twice as concentrated, every injection delivers 2× the tirzepatide.
- Shaking the vial. Tirzepatide is a peptide. Vigorous shaking foams it and denatures the protein. Swirl gently; let it sit 1–2 minutes to fully dissolve.
- Using sterile water instead of bacteriostatic water for a multi-dose vial. Without the benzyl alcohol preservative, the vial is no longer protected against microbial growth past 24 hours.
- Not refrigerating after reconstitution. Stability data supports 28 days at 2–8°C. Some community sources cite longer; that is unvalidated.
- Re-using needles. Beyond contamination risk, re-used needles core the vial stopper and introduce dose-volume errors.
Side effects and management
From the SURMOUNT-1 trial (Jastreboff et al., NEJM 2022; 387:205–216), the most common side effects at the 15 mg dose were:
- Nausea , 29%
- Diarrhea , 23%
- Constipation , 17%
- Vomiting , 13%
- Abdominal pain , 10%
- Injection-site reactions , 8%
- Fatigue , 7%
- Alopecia (hair shedding) , 5–6%, more frequent than with semaglutide
The GI burden is dose-dependent and front-loaded to the first few weeks of each new step. Most patients find that nausea peaks 24–48 hours after injection and recedes through the rest of the week. Hair shedding (technically telogen effluvium) is most often attributed to rapid weight loss rather than a direct drug effect, and it usually resolves once weight stabilizes.
Tirzepatide carries the same boxed warning for thyroid C-cell tumors as the rest of the GLP-1 class (rodent data; human relevance unclear). It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.
Less common but worth knowing about: pancreatitis (~0.2% per year), gallbladder disease, and hypoglycemia when combined with sulfonylureas or insulin. As monotherapy in non-diabetic patients, hypoglycemia is rare.
Practical management strategies
- Hold the current titration step for an extra 2–4 weeks if you are not tolerating it. The Zepbound label explicitly permits this.
- Some prescribers co-prescribe ondansetron during the early weeks of titration.
- Hydration matters , aim for 2–3 L of water daily. Volume depletion from vomiting is the leading cause of acute kidney injury on this drug class.
- Smaller, lower-fat meals reduce nausea more than any other dietary change.
- Down-titrating one step is explicitly permitted by the label if a higher dose is intolerable.
Drug interactions
Drug interactions to know
Educational summary only, not medical advice. Consult your prescriber. See full interactions lookup.
Cycle Lengths
Cycling summary: Continuous per FDA label; miss window 4 days.
Chronic-use peptides like Tirzepatide (Mounjaro / Zepbound) are typically continued as long as the treatment goal is active. Intentional pauses may be indicated for pregnancy planning, scheduled surgery, or transition to maintenance dosing (peptide-specific). See the peptide’s FDA prescribing information or your prescribing clinician for personalized guidance.
Lab Monitoring
Tirzepatide (Mounjaro / Zepbound) is a GLP-1 class agent with a well-characterized monitoring profile. Both the intended metabolic effect (glucose, weight, lipids) and class-associated risks (thyroid, pancreatic, gallbladder, retinopathy) warrant structured lab tracking.
Baseline (before starting): HbA1c, fasting glucose, lipid panel, comprehensive metabolic panel (CMP) with LFTs and renal function, CBC, TSH, amylase and lipase if pancreatic risk is present, and serum calcitonin if there is a personal or family history of medullary thyroid carcinoma (contraindication per class labels).
During use: HbA1c and lipid panel every 3 months during titration, then every 6 months once stable. CMP every 3-6 months. Weight and blood pressure monthly during titration. Gallbladder ultrasound if new right-upper-quadrant pain (increased gallbladder disease risk documented across the GLP-1 class).
What to flag to a physician: persistent severe abdominal pain (pancreatitis rule-out), right-upper-quadrant pain (gallbladder), new neck mass or dysphagia (thyroid), worsening vision if diabetic, pregnancy or plans for pregnancy.
For the full class-wide monitoring framework and a plain-language comparison of DTC lab services for peptide users, see the Peptide Lab Testing pillar guide.
Storage & Travel
Storage
Lyophilized powder: Refrigerate 2-8°C (36-46°F); protect from light; do not freeze.
Reconstituted: In-use pen up to 21 days at 15-30°C (59-86°F) or refrigerated; do not return to fridge after room temp. Never freeze a reconstituted vial, since freeze-thaw cycles damage peptide bonds and reduce potency.
Travel
Pen advantage: the auto-injector or pen form of Tirzepatide (Mounjaro / Zepbound) is typically stable at room temperature for weeks after first use, which makes travel simpler than compounded vials. Check the specific pen’s labeled room-temperature stability window.
Domestic flights: carry pens in original labeled packaging; TSA permits medications through security. Declare and keep pens visible if asked.
International travel: carry the prescription label, a physician’s letter, and the FDA product insert. Some countries require import declaration for injectable medications.
Road trips: keep pens in the cabin, not the trunk, during summer heat (trunk temps regularly exceed 40°C).
Common stacks and combinations
Within FDA-approved use, tirzepatide is frequently combined with metformin (especially in T2DM), SGLT2 inhibitors, and statins. None of these combinations require dose adjustment of tirzepatide itself.
Two combinations require caution:
- Sulfonylureas and insulin. Adding tirzepatide to either substantially increases hypoglycemia risk. Most prescribers reduce the sulfonylurea or basal insulin dose at the time tirzepatide is started.
- Oral medications with narrow absorption windows. Tirzepatide slows gastric emptying, which can blunt the absorption of oral contraceptives and some antibiotics during the first 4 weeks and after dose escalations. The Zepbound label recommends a non-oral or barrier contraceptive during initiation and for 4 weeks after each dose increase.
In the biohacker community, tirzepatide is sometimes stacked with metformin for additive metabolic effect or with low-dose growth hormone secretagogues for body composition. These are off-label, not validated in clinical trials, and outside the scope of FDA-labeled use.
2026 regulatory status
The compounded tirzepatide market is the most contested area of GLP-1 prescribing in 2026. Here is the timeline:
- October 2024: The FDA declared the tirzepatide shortage resolved, removing the legal basis for routine 503A/503B compounding of “essentially a copy” of branded tirzepatide.
- Late 2024 – 2025: Most large telehealth compounders pivoted to “personalized” formulations , typically tirzepatide combined with another active ingredient such as B6 , claiming this falls outside the “essentially a copy” definition. The FDA and several state pharmacy boards have challenged this interpretation.
- 2026 (current): Availability and legality of compounded tirzepatide vary materially by state and by pharmacy. Patients should ask their telehealth provider directly whether the formulation is FDA-permitted in their state and request the compounding pharmacy’s certificate of analysis.
Branded Mounjaro and Zepbound are unaffected by any of this , they remain FDA-approved and widely available.
Cost considerations
| Product | Cash price (April 2026) | Notes |
|---|---|---|
| Mounjaro pens | ~$1,080/month | Routinely covered for T2DM |
| Zepbound pens | ~$1,060/month | Coverage for obesity remains spotty |
| Zepbound vial via LillyDirect (2.5 mg) – Self Pay Journey Program | $299/month | Self-pay channel, Feb 2026 update |
| Zepbound vial via LillyDirect (5 mg) – Self Pay Journey Program | $399/month | Self-pay channel |
| Zepbound vial via LillyDirect (7.5 mg / 10 mg / 12.5 mg / 15 mg) – Self Pay Journey Program | $449/month (45-day refill) | Self-pay channel |
| Zepbound vial via LillyDirect (standard self-pay) 7.5 mg / 10 mg / 12.5 mg / 15 mg | $599-$1,049/month | Standard self-pay tier |
| Compounded tirzepatide via telehealth | $200–$500/month | Highly variable; legal status varies by state |
Zepbound for OSA gained broader insurance coverage in 2025 after the December 2024 indication add. Coverage for obesity alone remains carve-out-dependent , the Mercer 2025 Survey found roughly 40–50% of large-employer plans cover Wegovy or Zepbound for obesity in 2026.
Frequently asked questions
Is Mounjaro the same drug as Zepbound?
Yes. Identical molecule, identical strengths, identical titration. Different brand names because they are approved for different indications: Mounjaro for type 2 diabetes, Zepbound for chronic weight management and OSA in obesity (HFpEF is under investigation, not yet FDA-approved).
Do I have to escalate to 15 mg?
No. The label lists 5, 10, and 15 mg as the core maintenance options. Many patients respond durably at 7.5 or 10 mg. Real-world SURMOUNT-1 extension data supports this. Stay where you are responding well and tolerating side effects , escalation is not a goal in itself.
What happens if I miss a dose?
Per the FDA label: if it has been less than 4 days since your missed dose, take it as soon as you remember and resume your normal weekly schedule. If more than 4 days, skip it and take the next dose on its regular day. Never double up. If a gap exceeds 2 weeks, prescribers commonly down-titrate one step before resuming.
Can I switch from semaglutide to tirzepatide?
Yes, and many patients do. There is no FDA-validated conversion table, but the most widely used clinical heuristic puts 1 mg semaglutide roughly equivalent to 5–7.5 mg tirzepatide, and 2.4 mg semaglutide roughly equivalent to 10–12.5 mg tirzepatide. See our GLP-1 conversion guide for full ratios and the standard switch protocol.
Is compounded tirzepatide legal in 2026?
It depends on the state and the formulation. After the FDA’s October 2024 shortage resolution, routine 503A/503B compounding of tirzepatide as “essentially a copy” of the branded product became restricted. Many compounders now sell “personalized” formulations (e.g., tirzepatide + B6). Whether these comply with FDA and state pharmacy law is contested. Ask your telehealth provider directly about the legal basis in your state.
Where do I inject tirzepatide?
Subcutaneously into the abdomen, thigh, or back of the upper arm. Rotate sites weekly. The injection should go just under the skin, not into muscle.
Can I drink alcohol on tirzepatide?
The label does not prohibit it. In practice, most patients find alcohol tolerance drops noticeably , partly because of slowed gastric emptying, partly because GLP-1 activation appears to dampen the rewarding effects of alcohol. Many people report drinking less without trying.
How long do I stay on tirzepatide?
Long term. Like medications for hypertension or hypercholesterolemia, tirzepatide treats a chronic condition; appetite and weight typically rebound after discontinuation. Trial extension data shows weight regain of roughly half the lost weight within a year of stopping.
Disclaimer: This article is for educational purposes only. It is not medical advice and is not a substitute for consultation with a licensed healthcare provider. Dosing decisions , including starting, titrating, switching, or stopping tirzepatide , must be made with your prescribing physician. Compounded GLP-1 medications are subject to evolving FDA enforcement and state-level regulation; their legal availability may have changed since this page was published. Always read your medication’s FDA-approved prescribing information and follow your prescriber’s instructions.
- Demand a current third-party Certificate of Analysis (CoA) listing peptide identity (mass spec), purity ≥98%, and endotoxin testing.
- Verify the lyophilized vial weight matches what’s printed – under-filled vials are the most common form of dose-cheating in this market.
- Storage: Compounded tirzepatide is widely sold; pharmaceutical Mounjaro / Zepbound is the FDA-approved option.
- Typical research route: subcutaneous (weekly).
- 503A compounding pharmacies prepare tirzepatide off-label; quality varies. Pharmaceutical product is dramatically more consistent.
- “Research-use-only” labeling has legal weight – self-administration may violate state and federal law in your jurisdiction.
References
- U.S. Food and Drug Administration. Mounjaro (tirzepatide) prescribing information. DailyMed.
- U.S. Food and Drug Administration. Zepbound (tirzepatide) prescribing information. DailyMed.
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. NEJM.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. NEJM.
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide for obesity in adults with type 2 diabetes (SURMOUNT-2). Lancet. 2023. PubMed.
- Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for weight reduction maintenance (SURMOUNT-4). JAMA. 2024;331(1):38-48. PubMed.
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024. PubMed.
- American Diabetes Association. Standards of Care in Diabetes—2026. Diabetes Care. Diabetes Journals.
- U.S. Food and Drug Administration. Drug Shortages Database. FDA.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA.






